Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Antibiotics 2014, 3(2), 109-120; doi:10.3390/antibiotics3020109
Article

Clinical Efficacy of a Single Two Gram Dose of Azithromycin Extended Release for Male Patients with Urethritis

1,* , 2
, 3
, 4
, 1
, 1
, 1
, 1
, 1
, 5
, 5
, 5
, 6
, 7
, 7
 and 7
Received: 10 February 2014; in revised form: 26 February 2014 / Accepted: 4 March 2014 / Published: 2 April 2014
(This article belongs to the Special Issue Antibiotics and Urinary Tract Infections)
View Full-Text   |   Download PDF [601 KB, uploaded 2 April 2014]
Abstract: To clarify the clinical efficacy of a single oral 2 g dose of azithromycin extended-release for heterosexual male patients with urethritis, and the current antimicrobial sensitivity of Neisseria gonorrhoeae to azithromycin, a prospective clinical trial was conducted from 2011–2013. In patients with gonococcal urethritis, the eradication rate was 90.9% (30 of 33). The susceptibility rates of isolated Neisseria gonorrhoeae strains to ceftriaxone, spectinomycin, cefixime and azithromycin were 100%, 100%, 95.3% (41/43) and 37.2% (16/43), respectively. In the patients with nongonococcal urethritis, the eradication rate was 90.0% (45 of 50). The microbiological eradication rates for the pathogens were 90.9% (30/33) for Neisseria gonorrhoeae, 91.5% (43/47) for Chlamydia trachomatis, 71.4% (5/7) for Mycoplasma genitalium, and 100% (13/13) for Ureaplasma urealyticum. The main adverse event was diarrhea and its manifestation rate was 35.2% (32 of 120). The symptom of diarrhea was mostly temporary and resolved spontaneously. The conclusion was that the treatment regimen with a single oral 2 g dose of azithromycin extended-release would be effective for patients with urethritis. However, the antimicrobial susceptibilities of Neisseria gonorrhoeae and Mycoplasma genitalium should be carefully monitored because of possible treatment failure.
Keywords: azithromycin; extended release; urethritis; Neisseria gonorrhoeae; Chlamydia trachomatis; Mycoplasma genitalium; Ureaplasma urealyticum azithromycin; extended release; urethritis; Neisseria gonorrhoeae; Chlamydia trachomatis; Mycoplasma genitalium; Ureaplasma urealyticum
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Takahashi, S.; Kiyota, H.; Ito, S.; Iwasawa, A.; Hiyama, Y.; Uehara, T.; Ichihara, K.; Hashimoto, J.; Masumori, N.; Sunaoshi, K.; Takeda, K.; Suzuki, N.; Hosobe, T.; Goto, H.; Suzuki, H.; Onodera, S. Clinical Efficacy of a Single Two Gram Dose of Azithromycin Extended Release for Male Patients with Urethritis. Antibiotics 2014, 3, 109-120.

AMA Style

Takahashi S, Kiyota H, Ito S, Iwasawa A, Hiyama Y, Uehara T, Ichihara K, Hashimoto J, Masumori N, Sunaoshi K, Takeda K, Suzuki N, Hosobe T, Goto H, Suzuki H, Onodera S. Clinical Efficacy of a Single Two Gram Dose of Azithromycin Extended Release for Male Patients with Urethritis. Antibiotics. 2014; 3(2):109-120.

Chicago/Turabian Style

Takahashi, Satoshi; Kiyota, Hiroshi; Ito, Shin; Iwasawa, Akihiko; Hiyama, Yoshiki; Uehara, Teruhisa; Ichihara, Koji; Hashimoto, Jiro; Masumori, Naoya; Sunaoshi, Kenichi; Takeda, Koichi; Suzuki, Nobukazu; Hosobe, Takahide; Goto, Hirokazu; Suzuki, Hidenori; Onodera, Shoichi. 2014. "Clinical Efficacy of a Single Two Gram Dose of Azithromycin Extended Release for Male Patients with Urethritis." Antibiotics 3, no. 2: 109-120.

Antibiotics EISSN 2079-6382 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert